TRex Bio IPO Priced at Bottom of Expectations

Dow Jones2026/10/09 09:54

By Colin Kellaher Shares of TRex Bio are slated to make their trading debut Friday after the clinical-stage biotechnology company's initial public offering was priced at the low end of expectations, raising about $116.7 million. The South San Francisco, Calif., company late Thursday said it is selling more than 8.33 million shares at $14 each, compared with an expected price range of $14 to $16. TRex shares are due to begin trading later Friday on the Nasdaq Global Select Market under the symbol TRXB. Write to Colin Kellaher at colin.kellaher@wsj.com (END) Dow Jones Newswires October 09, 2026 05:54 ET (09:54 GMT)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

UK funds significantly reduced their holdings in SpaceX last week and had fully exited Tesla as of April.

格隆汇•2026/11/09 05:55

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45

Sun Machinery CEO Park Kyung-hee Raises Stake to 8.40% From 8.31%

Bitget•2026/11/09 05:37

The central bank has increased its gold reserves for 24 consecutive months, with October’s increase hitting a record high for the period.

新浪财经•2026/11/09 05:37